For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for IQVIA Holdings Inc. (IQV) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -21 (−100…+100 Quality+Value blend) · Quality 37 · Value -68 · Sentiment 43 (timing only, not weighted) · Composite fair value $154.39 vs $259.82 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
IQVIA Holdings Inc.
IQV NYSEIQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company supports pharmaceutical, biotechnology, medical device, and healthcare organizations in developing, testing, and commercializing therapies using extensive real-world data, predictive analytics, and technology platforms. Its Technology and Analytics Solutions segment delivers healthcare data, decision-support tools, and software to clients such as manufacturers, providers, payers, and policymakers, helping them optimize clinical and commercial performance. The Research and Development Solutions segment focuses on outsourced clinical trial services, including late-stage and virtual clinical trials for drugs, devices, and diagnostics. IQVIA also offers contract sales and medical solutions that assist with commercialization and field-based engagement. Founded in 1950 and headquartered in Durham, North Carolina, IQVIA plays a central role in the healthcare ecosystem by enabling more efficient evidence generation, regulatory submissions, and market access strategies across more than 100 countries worldwide.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 7.84
Total Equity: $6.63B
Shares: 173,500,000
Total Debt: $15.72B
Cash: $1.98B
EBITDA: $3.33B
Total Debt: $15.72B
Cash: $1.98B
Revenue: $16.31B
Revenue: $16.31B
Revenue: $16.31B
Total Equity: $6.63B
Tax Rate: 15.8%
Equity: $6.63B
Total Debt: $15.72B
Cash: $1.98B
Current Liabilities: $8.34B
Long-Term Debt: $13.88B
Total Debt: $15.72B
Total Equity: $6.63B
Shares: 173,500,000
Shares: 173,500,000
CapEx: -$603.00M
Shares: 173,500,000
Stock Price: $259.82
Net Income: $1.36B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 22, 2026 4:24pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $13.9B | $14.4B | $15.0B | $15.4B | $16.3B |
| Cost of Revenue | $9.2B | $9.4B | $9.7B | $10.0B | $10.9B |
| Gross Profit | $4.6B | $5.0B | $5.2B | $5.4B | $5.4B |
| Operating Expenses | $3.2B | $3.2B | $3.3B | $3.2B | $3.2B |
| Operating Income | $1.4B | $1.8B | $2.0B | $2.2B | $2.2B |
| Net Income | $966.0M | $1.1B | $1.4B | $1.4B | $1.4B |
| EBITDA | $2.7B | $2.9B | $3.1B | $3.3B | $3.3B |
| EPS | $5.05 | $5.82 | $7.39 | $7.57 | $7.91 |
| EPS (Diluted) | $4.95 | $5.72 | $7.29 | $7.49 | $7.84 |
Balance Sheet (Annual)
Last updated: Aug 22, 2026 4:05pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.4B | $1.2B | $1.4B | $1.7B | $2.0B |
| Total Current Assets | $4.8B | $5.0B | $5.6B | $5.8B | $6.2B |
| Total Assets | $24.7B | $25.3B | $26.7B | $26.9B | $29.9B |
| Current Liabilities | $5.2B | $5.6B | $6.5B | $7.0B | $8.3B |
| Long-Term Debt | $12.0B | $12.6B | $13.0B | $12.8B | $13.9B |
| Total Liabilities | $18.6B | $19.6B | $20.6B | $20.8B | $23.3B |
| Total Equity | $6.0B | $5.8B | $6.1B | $6.1B | $6.6B |
| Retained Earnings | $2.2B | $3.3B | $4.7B | $6.1B | $7.4B |
Cash Flow (Annual)
Last updated: Aug 22, 2026 4:24pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.9B | $2.3B | $2.1B | $2.7B | $2.7B |
| Capital Expenditure | -$640.0M | -$674.0M | -$649.0M | -$602.0M | -$603.0M |
| Free Cash Flow | $2.3B | $1.6B | $1.5B | $2.1B | $2.1B |
| Acquisitions (net) | -$1.5B | -$1.3B | -$876.0M | -$735.0M | -$1.7B |
| Net Debt Issued / (Repaid) | -$140.0M | $616.0M | $1.1B | -$172.0M | $1.3B |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$406.0M | -$1.2B | -$992.0M | -$1.4B | -$1.2B |
| Net Change in Cash | -$448.0M | -$150.0M | $160.0M | $326.0M | $278.0M |
Growth Trends (YoY %)
Last updated: Aug 22, 2026 4:24pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +3.9% | +4.0% | +2.8% | +5.9% |
| Gross Profit Growth | +8.3% | +4.2% | +2.6% | +1.0% |
| Operating Income Growth | +29.1% | +9.9% | +11.4% | -0.9% |
| Net Income Growth | +12.9% | +24.5% | +1.1% | -0.9% |
| EBITDA Growth | +10.2% | +5.9% | +6.9% | +0.3% |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-22 16:37Even the bull case prices 3% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 73%.
| Case | Growth | Margin | Fair value | vs price ($259.82) |
|---|---|---|---|---|
| Bull — recovery | +12% | 24.6% | $250.90 | -3% |
| Base — stabilizes | +8% | 21.4% | $193.07 | -26% |
| Bear — keeps slipping | +4% | 18.2% | $145.27 | -44% |
| Stress — last quarter repeats | +5% | 7.7% | $69.79 | -73% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-22 16:35The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw numbers tell a story of a business that has essentially stopped growing at the bottom line while carrying a leveraged balance sheet. Annual net income has been flat at ~$1.36B for three straight years (2023: $1.36B, 2024: $1.37B, 2025: $1.36B) despite revenue climbing from $14.98B to $16.31B — that's operating leverage running in reverse. Gross margin has been grinding lower (36.2% in 2022 → 33.3% in 2025), and the most recent quarter (Q1 2026) shows revenue of $4.15B with NI of just $274M (6.6% margin) — worse than Q1 2025's already-weak 6.5%. Debt of $15.72B against $6.63B equity (D/E 2.37) and cash of only $1.98B against a current ratio of 0.75 is not a "mature earner" balance sheet; it's a leveraged one that requires refinancing discipline in a still-elevated rate environment. FCF of $2.05B is real, but at a $42.8B market cap plus ~$13.7B net debt, EV/FCF is ~27x for a business growing revenue at ~5% and earnings at 0%.
The synthesis verdict ($124–154 fair value vs $260) is directionally right but I think the magnitude is aggressive. A DCF that spits out $154 on a business generating $2.05B of FCF implies you're assigning almost no terminal value credit to the data/TAS optionality — which is the whole reason IQV trades where it does. The Pre-Flight and Narrative layers correctly identify that the market is paying a platform-monopoly multiple for what the P&L actually shows: a services grinder with 13.4% operating margins and no earnings growth. But Market Forces calling this a "deteriorating incumbent losing massive market share" overstates it — revenue is still growing 5.9% YoY and FCF CAGR of 16.9% (though this is partially working-capital driven and not matched by earnings CAGR of 0.1% — a red flag the synthesis undersells). The contradiction between "Strong Cash Flow Quality" and 0.1% earnings CAGR deserves more scrutiny: either D&A/SBC is masking real economic earnings, or working capital tailwinds are non-repeatable. I lean toward the latter given flat NI.
The contrarian case worth stress-testing: IQV's real-world data assets (IMS legacy + Q² acquisition + decades of trial data) genuinely are hard to replicate, and if biotech funding recovers in 2026-27, the CRO backlog could re-accelerate. Pharma R&D spend has been resilient at $250B+ globally, and GLP-1/oncology trial demand is structurally growing. At a $154 fair value the stock would trade at ~19x earnings and ~11x EV/EBITDA — that's pricing in secular decline, not maturity. The insider activity is unambiguously negative but modest in size (mostly option-exercise-and-sell mechanics, ~114K net shares sold across the cluster) — I wouldn't weight it heavily. What I would weight: the flat three-year earnings profile combined with gross margin compression from 36% to 33% suggests pricing power is eroding, not building — which directly contradicts the platform-monopoly narrative.
I partially agree with the synthesis but dissent on magnitude. Fair value is closer to $190–210, not $124. Getting to $154 requires assuming margin compression continues and multiple compresses to peer CRO levels (~15x) — plausible bear case but not base case for a business with genuine data moat elements. Getting to $260 requires the market's implied 25% FCF CAGR — implausible given the flat earnings trajectory and 33% gross margin. At $260, IQV is priced for a re-acceleration that the numbers do not support: Q1 2026 revenue growth of 8.4% YoY is fine, but the margin regression is not. The insider file, macro headwinds tag, and lagging sector peers signal all point the same direction, and the thesis evaluation's -8 score with bear mass of 88 vs bull mass of 80 is roughly where I land. This is a "wait for $195 or a re-rating catalyst" situation, not a "load the boat short" one. Data is reasonably current (Q1 2026 print available), but the 2026-dated insider transactions and quarterly data suggest the file has been synthetically forward-dated or contains a labeling quirk — worth flagging but doesn't change the analytical read.
GPT Reading
IQVIA looks like a good business priced like a better one. The raw numbers say “steady compounder,” not “platform step-change.” Revenue has climbed from $13.87B in 2021 to $16.31B in 2025, about 4% annualized, and the quarterly run-rate shows the same mid-single-digit pace: 2026 Q1 revenue of $4.15B was up 8.4% from $3.83B a year earlier, following 2025 growth that was decent but hardly explosive. The issue is that earnings have not followed. Net income was $1.36B in 2023, $1.37B in 2024, and $1.36B again in 2025. So after two years of revenue growth, net income is flat. That is the central fact the valuation has to overcome, and at 33x earnings, 17.6x EV/EBITDA, and 2.8x sales, I don’t think it does.
Margins reinforce that this is a scale services business with limited incremental drop-through, not a software-like model hiding inside healthcare outsourcing. Gross margin was 35.7% in 2024 and fell to 33.3% in 2025 despite revenue growth. Operating income actually slipped from $2.20B to $2.18B year over year. Quarterly net margins are also choppy: 6.5%, 6.6%, 8.1%, 11.8%, then back to 6.6% in the latest quarter. Some seasonality is normal, but if the bull case is that data assets and analytics should steadily enrich mix and expand profitability, the reported pattern doesn’t show it yet. IQVIA does generate real cash — $2.65B of operating cash flow and $2.05B of free cash flow in 2025 is strong, roughly a 12.6% FCF margin — but even that only gives an FCF yield of about 4.8% on a $42.8B market cap. For a business growing revenue mid-single digits and earnings not at all, that is not cheap.
The balance sheet is the other reason I lean bearish rather than merely cautious. Debt is $15.72B against $1.98B of cash, so net debt is roughly $13.7B. Against 2025 operating income of $2.18B and ROIC of 9.0%, leverage is meaningful, especially with a current ratio below 0.75. This is not distress territory because the business is cash generative, but it absolutely matters for equity valuation: a highly levered mature services company should not command a premium multiple unless margin expansion or growth acceleration is evident. Instead, equity is only $6.63B, so the capital structure is doing a lot of the work in boosting ROE to 20.5%; that number flatters the economics more than it proves exceptional underlying returns. I also would not overread the insider sales, since option exercise-related selling is common, but the tape certainly doesn’t offer a counter-signal that management thinks the shares are glaringly cheap.
The best argument against my view is that IQVIA is not just a CRO, and the market may be correctly valuing durability over growth. A business that can produce over $2B of annual free cash flow, hold net income around $1.3B through mixed pharma spending cycles, and grow revenue from $14.98B to $16.31B in two years without blowing up margins does deserve a premium to lower-quality outsourced services names. You can also argue that 2025’s weaker gross and operating margins are temporary mix effects rather than structural deterioration, and that the latest quarter’s 8.4% revenue growth hints at reacceleration. If free cash flow can keep compounding faster than earnings — as it has over the past few years — then a P/E screen may be too punitive, particularly for a company with recurring customer relationships and embedded data assets. That is the strongest bull case: resilience plus cash conversion plus strategic positioning.
I’d still weigh those positives below the price because the market seems to be paying today for margin and growth that remain prospective. To change my mind, I would want to see two things in the reported numbers, not just in the narrative: first, sustained operating leverage, meaning annual operating income grows meaningfully faster than revenue and operating margin moves back above 14% rather than hovering around 13%; second, free cash flow pushing toward $2.6B-$3.0B without leverage increasing, which would make the current enterprise value look more reasonable. If the next few quarters show revenue holding above 7-8% growth while net margin stabilizes closer to 9-10% instead of 6-7%, the stock can support a higher base than I’m giving it. Absent that, $260 looks like a full price for a business whose actual reported earnings power has been flat.
Grok Reading
The numbers on IQVIA describe a mature cash compounder that the market insists on valuing like a growth platform. Revenue climbed from $13.87B in 2021 to $16.31B in 2025—a 4.3% CAGR—with the latest year at 5.9% growth to $16.31B. That is respectable scale, not acceleration. Net income has gone nowhere: $1.36B in 2023, $1.37B in 2024, $1.36B in 2025, and trailing quarterly NI swinging between $249M and $514M with no upward slope (earnings CAGR essentially 0.1%, recent YoY −1%). Operating margin sits at 13.4% and net margin at 8.3%, both capped; gross margin of 33.3% has barely moved despite years of “tech-enabled” narrative. What does work is cash conversion: $2.65B operating CF and $2.05B FCF on $603M capex, an FCF CAGR of 16.9% that is the only metric justifying any premium. At a $42.8B equity value and roughly $56.5B EV (net debt ≈ $13.7B), you are paying ~21× FCF and 17.6× EV/EBITDA for mid-single-digit top-line growth and flat earnings. A 33× P/E on a business whose earnings have not compounded in three years is the core mismatch.
The balance sheet sharpens the risk. Total debt of $15.72B against $6.63B equity (D/E 2.37) and a current ratio of 0.75 leave little cushion; ROIC of 9.0% and ROA of 4.5% show that the 20.5% ROE is leverage theater, not superior capital returns. Quarterly revenue is grinding higher—$3.83B → $4.02B → $4.10B → $4.36B → $4.15B—but the margin pattern remains seasonal and unexpanded (Q1s stuck near 6.5–6.6%, one strong Q4 at 11.8%). Insider activity in mid-2026 was a wave of sales and option-related dispositions, not accumulation. The prior models’ “overvalued” call and the −8 thesis score align with the raw data: the stock embeds an implied path to something like 25% FCF growth that the income statement simply does not support. The platform-monopoly narrative is doing the heavy lifting; the fundamentals are a mid-single-digit CRO/data services grinder with high leverage.
The strongest case against this read is the FCF engine and the durability of the data franchise. Free cash flow of $2.05B with strong conversion quality is real, and if the 16.9% FCF CAGR persists while revenue merely compounds at 5–6%, equity value can still accrete even without multiple expansion. Pharma R&D outsourcing remains structural, hybrid/decentralized trials are a multi-year mix shift, and IQVIA’s real-world data assets are genuinely hard to replicate at scale—arguments the bull camp (and the 33× multiple) lean on. A smart opponent would also note that EV/revenue of 3.6× and P/S of 2.8× are not outrageous for a sticky healthcare infrastructure name if margins ever inflect, and that FCF yield near 5% is not zero in a quality compounder. I weigh this less heavily because earnings have stagnated, ROIC is mediocre after leverage, debt service and refinancing risk are non-trivial at $15.7B of debt, and every year without operating leverage makes the “AI/data monopoly” story look more like marketing cover for a services ceiling already visible in the 13% operating margin.
What would flip the verdict is concrete evidence that the narrative is becoming the P&L: two consecutive quarters of revenue growth sustainably above 8–9% with operating margin pushing through 15%, a clear multi-year path to $3B+ FCF without further leverage, and net debt/EBITDA trending down materially rather than sideways. A credible capital-return step-up (debt paydown plus buybacks) funded by FCF, or segment disclosure showing the analytics/TAS mix actually expanding margins, would also force a re-rating higher. Absent that, the $260 print remains a story price on mature-earner economics.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
IQVIA is a mature earner: revenue grew from $13.87B (2021) to $16.31B (2025), a ~4% CAGR, with operating margin expanding from 10% to a 14.3% peak in 2024 before easing to 13.4% in 2025. Gross margin has been stable in the 33-35% band, and FCF has run $1.5-2.3B annually, funding a genuine per-share value story: diluted shares fell from 195.0M to 173.5M (-2.9% CAGR) with buybacks running ~5x SBC and SBC only 1.5% of revenue. Earnings quality checks are clean: OCF/NI 2.13x, accruals -5% of assets, Beneish M -2.59.
Verify before trusting this (5)
- Composition and maturity ladder of the $13.58B net debt and refinancing risk
- Cause of 2025 operating margin compression (mix, pricing, or one-time)
- Backlog and book-to-bill trends in the R&D Solutions segment
- Customer concentration among top biopharma clients
- Whether SBC is being netted against buyback authorization or on top
Every valuation lane lands well below the tape: DCF $158.75, anchored P/E $202.02, and an EPV floor of just $98.03, blending to a composite fair value of $154.39 and a signal-adjusted $123.95. Even the most generous of those, the anchored P/E, still implies about 22% downside from $259.82. The earnings-quality read is clean (score 2), so there is no haircut to apply, and the Company-Quality lens is only 'Solid' with real net debt - not a fortress that deserves a premium multiple on top of already-full lanes. The gap is the whole story: you are paying for the bull's platform-monopoly narrative in full. To justify $260 you need durable mid-to-high-single-digit revenue growth, margin expansion despite 2025's early margin fatigue, and continued aggressive buybacks - a stack of things going right on a levered, mature CRO. The bear case (commoditized clinical services, 2.1x sales, leverage) is not priced in at all. This isn't obviously overvalued to the point of shorting - the anchored-PE lane and buyback compounding give some support - but there is no margin of safety here, and I would not underwrite a purchase at this price.
Verify before trusting this (4)
- 2026 organic revenue growth guide and R&DS backlog conversion rate
- Segment margin trajectory after 2025's dip - is it cyclical or structural?
- Net debt path and buyback pace relative to FCF
- Evidence of real pricing power or AI-data monetization beyond narrative
The prevailing narrative on IQV is a platform-monopoly / AI-enabled data story with strong intensity, and the news flow this week is feeding it directly: an AI Breakthrough Award headline reinforces the AI angle, and a fresh 'Is Wall Street Bullish?' piece frames analysts as highly optimistic. On top of that, the July 28 blowout quarter (top S&P gainer, +14%, raised guide, record bookings) is still the anchoring memory for this name - momentum and analyst tone are aligned to the upside. That is a real, persistent press on the tape, not just background noise.
Verify before trusting this (5)
- Whether analyst price-target revisions post Q2 keep climbing or stall
- Bookings/backlog color at next quarter - the linchpin of the platform story
- CRO peer tape (CRL, MEDP, ICLR) - if rotation reverses, IQV sentiment follows
- Any pharma R&D budget cut headlines that would crack the durability of the narrative
- VIX regime - a move back above 20 would disproportionately hit this beta-1.18 premium name
Two forces dominate. First, pharma is spending more on late-stage development into the 2027-2030 patent cliff while simultaneously running hard cost discipline on commercial and analytics budgets — that mix favours IQVIA's contracted trial work and pressures its higher-margin advisory/analytics line, which is exactly the pattern in the +8.4% revenue / +3.6% operating income split. Second, capital cost matters more than sentiment here: a 4.69% 10-year keeps emerging-biopharma trial starts subdued, and that cohort is where incremental outsourcing growth historically came from. AI is genuinely two-sided for this company: it can compress the billable-hour content of monitoring and data management (revenue risk), but IQVIA's proprietary longitudinal patient and prescription data is the scarce input models need, which is the one asset a competitor cannot rebuild. Net: a durable, slow-compounding business inside a faster-moving category.
When we made this prediction on Aug 23, 2026, IQV was $259.82. We expect it to be $232.00 by Feb 2027, and we consider it great value under $175.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 23, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.